According to Precedence Research, the global pet cancer therapeutics market size will grow from USD 493.01 million in 2025 to nearly USD 1,150.70 million by 2034, with an expected CAGR of 9.89% from 2025 to 2034.
Ottawa, Oct. 22, 2025 (GLOBE NEWSWIRE) — The global pet cancer therapeutics market size is expected to be worth over USD 1,150.70 million by 2034, increasing from USD 493.01 million in 2025. The market is growing at a strong CAGR of 9.89% between 2025 and 2034. The growing incidence of pet cancer and innovations in veterinary medicine drive market growth.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report@ https://www.precedenceresearch.com/sample/4351
The pet cancer therapeutics market is growing, driven by increasing awareness of pet cancer, rising pet humanization, growing pet ownership, and advancements in veterinary oncology. Pet cancer therapeutics are medical treatments that involve eradicating, diagnosing, and managing cancer in pets.
The diverse treatments of pet cancer are targeted therapy, radiation therapy, combination therapy, chemotherapy, immunotherapy, and surgery. The benefits of pet cancer therapeutics are monitoring treatment responses, reducing pain, extending the survival of pets, and improving the quality of life.
What are the Types of Pet Cancer Therapeutics?
➡️ Become a valued research partner with us ☎ https://www.precedenceresearch.com/schedule-meeting
Major Government Initiatives for Pet Cancer Therapeutics
Key Trends of the Pet Cancer Therapeutics Market
View Comprehensive Insights @ https://www.precedenceresearch.com/pet-cancer-therapeutics-market
Pet Cancer Therapeutics Market Opportunity
Growing Prevalence of Pet Cancer Unlocks Market Opportunity
The growing pet humanization and aging pet population increase the risk of pet cancer. The focus on better care for pet cancer and the focus on longer pet lifespan increase the risk of pet cancer. The growing awareness of cancer symptoms and a strong focus on improving the survival rates of pets increase the adoption of pet cancer therapeutics.
The growing improvements in diagnostic capabilities and innovations in veterinary oncology help in the development of advanced pet cancer therapeutics. The growing awareness about the treatment of pet cancer and the development of immunotherapies & targeted therapies helps in treating pet cancer. The growing prevalence of pet cancer creates an opportunity for the growth of the market.
Pet Cancer Therapeutics Market Limitations and Challenges
High Treatment Cost Creates Hurdles in Market Expansion
Despite several benefits of therapeutics in pet cancer, the high treatment cost restricts the market growth. Factors like complex treatment regimens, the need for specialized diagnostics, and extensive drug development are responsible for high treatment costs.
The need for specialized laboratory & imaging technology and the development of new treatments increase the cost. The high cost of drug research and development of combination treatments increases the cost. The high treatment cost hampers the growth of the pet cancer therapeutics market.
Pet Cancer Therapeutics Market Scope
Set up a meeting at your convenience to get more insights instantly! https://www.precedenceresearch.com/schedule-meeting
Pet Cancer Therapeutics Market Regional Insights
Why North America Dominates the Pet Cancer Therapeutics Market?
North America dominated the market in 2024. The growing number of pet owners and the presence of specialized veterinary clinics & hospitals increase the adoption of pet cancer therapeutics. The presence of advanced healthcare infrastructure and high penetration of pet insurance helps the market growth. The growing prevalence of pet cancer and increasing awareness about pet cancer increase the adoption of pet cancer therapeutics, driving the overall market growth.
The U.S. is dominating the regional market due to its high pet ownership rates, strong emotional bond between owners and pets, and significant willingness to spend on advanced veterinary care. The country boasts a well-established veterinary healthcare infrastructure, widespread access to pet insurance, and a high concentration of specialized oncology services. Major pharmaceutical and biotech companies like Zoetis, Elanco, and Anivive Lifesciences are U.S.-based, driving innovation and commercial availability of cancer treatments.
How Big is the U.S. Pet Cancer Therapeutics Market?
According to Precedence Research, The U.S. pet cancer therapeutics market size is valued at USD 245,07 million in 2025 and is projected to reach approximately USD 581.9 million by 2034, with a CAGR of 10.08% from 2025 to 2034.
Note: This report is readily available for immediate delivery. We can review it with you in a meeting to ensure data reliability and quality for decision-making.
Try Before You Buy – Get the Sample Report@ https://www.precedenceresearch.com/sample/4351
Asia Pacific Pet Cancer Therapeutics Market
Asia Pacific experiences a notable growth in the market during the forecast period. The growing awareness about pet cancer and the focus on increasing the lifespan of pets increase demand for pet cancer therapeutics. The growth in pet ownership and advancements in veterinary oncology help the market grow. The availability of diverse treatments like targeted therapies & immunotherapy, and supportive government policies for veterinary research, supports the overall growth of the market.
Country-Level Investments and Funding in the Pet Cancer Therapeutics Industry:
Pet Cancer Therapeutics Market Segmentations Outlook
Therapy Outlook
Why did the Chemotherapy Segment Dominate the Pet Cancer Therapeutics Market?
The chemotherapy segment dominated the market in 2024. The growing prevalence of various cancers, such as osteosarcoma, lymphoma, and mast cell tumors, increases demand for chemotherapy. The need for specialized care in veterinary oncology and focus on the high success rate of treatments increases demand for chemotherapy. The various administration routes like intratumoral, intravenous, & oral, and focus on killing cancer cells, increase the adoption of chemotherapy, driving the overall market growth.
The immunotherapy segment is the fastest-growing in the market during the forecast period. The growing humanization of pets and focus on improving pets’ health increases the demand for immunotherapy. The strong focus on personalised medicine and the development of precision medicine increases the adoption of immunotherapy. The focus on fewer side effects of medicine and the growing cases of pet cancer increase demand for immunotherapy, supporting the overall market growth.
Applications Outlook
Which Application Held the Largest Share in the Pet Cancer Therapeutics Market?
The lymphoma segment held the largest revenue share in the market in 2024. The high prevalence of lymphoma in dogs and the increasing adoption of chemotherapy help the market growth. The strong focus on chronic disease management and the growing development of novel therapeutics like Laverdia-CA1 support lymphoma. The well-established veterinary hospitals and innovations in veterinary oncology drive the market growth.
The mast cell cancer segment is experiencing the fastest growth in the market during the forecast period. The growing number of pet owners and the increasing humanization of pets increases the risk of mast cell cancer. The aging pet population and well-established veterinary clinics help the market growth. The growing prevalence of mast cell cancer and a specialized veterinary oncology center support the overall growth of the market.
Case Study: Zoetis Inc. – Leveraging AI to Transform Veterinary Oncology
Overview
Zoetis Inc., a global leader in animal health, represents a key innovator in the pet cancer therapeutics market. As the demand for advanced veterinary oncology solutions rises, Zoetis has strategically integrated artificial intelligence (AI) into its diagnostic and therapeutic ecosystem to enhance early cancer detection and improve treatment precision. The company’s recent launch of the AI Masses diagnostic tool demonstrates a major step toward data-driven, real-time cancer diagnosis in pets.
The global pet cancer therapeutics market is expanding rapidly, projected to grow from USD 493.01 million in 2025 to USD 1,150.70 million by 2034 at a CAGR of 9.89%, according to Precedence Research. The increasing incidence of pet cancers — particularly mast cell tumors, osteosarcoma, and lymphoma — has created an urgent need for accurate, affordable, and minimally invasive diagnostic methods. Historically, delayed detection has led to limited treatment success and higher mortality rates among companion animals.
Zoetis, which already holds a dominant position in veterinary biologics and pharmaceuticals, identified a significant gap in the early detection segment. Recognizing that faster and more precise diagnostics could transform oncology outcomes, the company invested in artificial intelligence to complement traditional veterinary imaging and cytology.
Challenge
Veterinary oncologists face a critical challenge: timely and accurate cancer diagnosis in pets.
Conventional diagnostic methods — such as histopathology and biopsy — are time-consuming, invasive, and reliant on limited in-clinic expertise. Many veterinary practices lack advanced imaging infrastructure, leading to delayed referrals and reduced survival rates for affected pets. The industry needed a non-invasive, scalable, and intelligent diagnostic solution to support veterinarians across geographies.
Strategic Solution: AI-Driven Diagnostic Ecosystem
In June 2025, Zoetis launched AI Masses, a proprietary artificial intelligence platform designed to accelerate cancer detection in pets. The AI tool utilizes advanced machine learning algorithms trained on thousands of veterinary imaging datasets, enabling rapid identification of malignant masses during in-clinic examinations.
The introduction of AI Masses has delivered measurable benefits across multiple stakeholders in the veterinary oncology value chain.
Broader Implications for the Pet Cancer Therapeutics Market
The success of Zoetis’s AI-driven diagnostic strategy aligns with key trends shaping the pet cancer therapeutics industry, including:
Future Outlook
Zoetis plans to expand AI Masses globally, integrating advanced analytics for treatment response prediction and longitudinal cancer monitoring. The company is also exploring partnerships with research institutions under initiatives like the NCI Comparative Oncology Program to strengthen translational oncology insights.
By 2034, AI-driven diagnostics are expected to become a standard component of veterinary oncology, significantly boosting the adoption of targeted therapies, immunotherapy, and combination treatment regimens. Zoetis’s pioneering approach underscores how technology-enabled innovation can redefine clinical outcomes, market growth, and customer trust in the evolving landscape of pet healthcare.
Thank you for reading. You can also get individual chapter-wise sections or region-wise report versions, such as North America, Europe, or Asia Pacific.
Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/4351
Stay Ahead with Precedence Research Subscriptions
Unlock exclusive access to powerful market intelligence, real-time data, and forward-looking insights, tailored to your business. From trend tracking to competitive analysis, our subscription plans keep you informed, agile, and ahead of the curve.
Browse Our Subscription Plans@ https://www.precedenceresearch.com/get-a-subscription
About Us
Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.
➡️ Prostate Cancer Market: Explore how advanced therapies and early screening innovations are reshaping global treatment outcomes
➡️ Cancer Therapeutics and Biotherapeutics Market: Examine how biopharma breakthroughs are driving the next generation of cancer care
➡️ Prostate Cancer Diagnostics Market: See how precision diagnostics and AI-powered tools are improving prostate cancer detection rates
➡️ Companion Animal Drugs Market: Understand the growing demand for pet therapeutics amid rising animal healthcare awareness
➡️ Head and Neck Cancer Drugs Market: Discover emerging therapies and targeted treatments transforming survival outcomes
➡️ Animal Biotechnology Market: Analyze how genetic engineering and biotech innovations are redefining animal health and productivity
➡️ Lymphoma Treatment Market: Track advancements in immunotherapy and precision medicine shaping lymphoma management
➡️ Veterinary Medicine Market: Explore how preventive care and pharmaceutical R&D are expanding the veterinary landscape
➡️ Esophageal Cancer Market: Gain insights into novel treatment approaches addressing one of the most challenging cancer types
➡️ Veterinary API Market: Examine the evolving API supply chain powering global animal drug manufacturing
➡️ Veterinary Diagnostics Market: See how rapid testing and molecular diagnostics are advancing animal disease detection globally
